Show simple item record

dc.contributor.authorParsons, S. K.
dc.contributor.authorRodday, A. M.
dc.contributor.authorScharman, C.
dc.contributor.authorAndre, M.
dc.contributor.authorFederico, M.
dc.contributor.authorFriedberg, J. W.
dc.contributor.authorFriedman, D. L.
dc.contributor.authorGallamini, A.
dc.contributor.authorHay, A. E.
dc.contributor.authorHoskin, P.
dc.contributor.authorJohnson, P.
dc.contributor.authorKahl, B. S.
dc.contributor.authorKeller, F. G.
dc.contributor.authorKelly, K. M.
dc.contributor.authorMeyer, R. M.
dc.contributor.authorRadford, John A
dc.contributor.authorRaemaekers, J.
dc.contributor.authorZinzani, P. L.
dc.contributor.authorCohen, J. T.
dc.contributor.authorEvens, A. M.
dc.contributor.authorHo, L. C.
dc.date.accessioned2021-04-06T15:07:07Z
dc.date.available2021-04-06T15:07:07Z
dc.date.issued2020en
dc.identifier.citationParsons SK, Rodday AM, Scharman C, André M, Federico M, Friedberg JW, et al. The Hodgkin lymphoma international study for individual care (HoLISTIC): Enhancing decision making in pediatric and adult Hodgkin lymphoma (HL). Journal of Clinical Oncology. 2020;38(15_suppl):e20019-e.en
dc.identifier.doi10.1200/JCO.2020.38.15_suppl.e20019en
dc.identifier.urihttp://hdl.handle.net/10541/623877
dc.description.abstractBackground: Decision making in HL is complicated by clinical trial results that differ, a growing range of treatment options, and the absence of ideal, objective information on long term outcomes from modern therapy. Methods: We formed an international consortium, HoLISTIC, consisting of 50+ pediatric & adult HL providers, decision scientists, statisticians, epidemiologists, and patient (pt) advocates and are creating a data repository of individual pt data (IPD) from 16 contemporary, pediatric & adult clinical trials for newly diagnosed pts with HL, and 6 large HL registries/survivorship cohorts, the latter enriched with LE data (Table). We will enhance our prior decision model (DM) from group-level data (Parsons S et al. B J Haem 2018) to establish a dynamic HL DM from IPD. Using statistical and simulation modeling of IPD, the enhanced DM will project outcomes of interest, including quality-adjusted life years (QALYs), reflecting both mortality and morbidity. Results will be validated and calibrated against prominent external cohorts (e.g., St. Jude LIFE Cohort, Dutch HL registry). The DM then will be converted to a web-based platform that we will test and evaluate among HL providers and pts at the point of care. Results: To date, we have harmonized IPD from 10 trials (~8,000 HL pts), ranging in size from 165-1925 pts. At diagnosis, median age was 26 y (IQR 18-38); 51.5% were male. 43% had B symptoms, 34% had mediastinal bulk, and 79% had nodular sclerosis histology. Median follow up was 5.0 y (IQR 3.5-7.4). IPD harmonization is ongoing, which will be followed by creation of the enhanced DM. Conclusions: HoLISTIC capitalizes on a multidisciplinary pediatric & adult oncology collaborative, harmonizing extensive IPD by linking data from clinical trials and real world registries/survivorship cohorts. This work will inform questions about the influence of Tx options on both acute and potential long term events and how those options align with pt values and preferences.en
dc.language.isoenen
dc.relation.urlhttps://dx.doi.org/10.1200/JCO.2020.38.15_suppl.e20019en
dc.titleThe Hodgkin lymphoma international study for individual care (HoLISTIC): Enhancing decision making in pediatric and adult Hodgkin lymphoma (HL)en
dc.typeMeetings and Proceedingsen
dc.contributor.departmentTufts Medical Center, Boston, MAen
dc.identifier.journalJournal of Clinical Oncologyen
dc.description.noteen]


This item appears in the following Collection(s)

Show simple item record